After winning accelerated approval, Lilly ’s cancer drug fails in study

An Eli Lilly treatment for advanced soft-tissue sarcoma missed the mark in a phase 3 study and will no longer be prescribed.

Source: PharmaManufacturing.com - January 21, 2019 Category: Pharmaceuticals Source Type: news